# Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

> **NCT03842696** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 43 (actual)

## Conditions studied

- Hematologic Diseases
- Acute Leukemia in Remission
- Chronic Myelogenous Leukemia - Chronic Phase
- Chronic Myelogenous Leukemia, Accelerated Phase
- Chronic Myelogenous Leukemia, Blastic Phase
- Myelodysplastic Syndromes
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Diffuse Large B Cell Lymphoma
- Non Hodgkin Lymphoma
- Graft Vs Host Disease
- Graft-versus-host-disease

## Interventions

- **DRUG:** Vorinostat
- **PROCEDURE:** Blood and Marrow Transplant (BMT)
- **DRUG:** Tacrolimus (or cyclosporine)
- **DRUG:** Methotrexate
- **DRUG:** Mycophenolate Mofetil (MMF)
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03842696
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-04
- **Primary completion:** 2025-07-30
- **Final completion:** 2026-04-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03842696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03842696, "Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03842696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*